HIV care cascade for women living with HIV in the Greater Toronto Area versus the rest of Ontario and Canada.
CHIWOS
Canada
Greater Toronto Area
HIV cascade of care
Women
Journal
International journal of STD & AIDS
ISSN: 1758-1052
Titre abrégé: Int J STD AIDS
Pays: England
ID NLM: 9007917
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
pubmed:
22
11
2022
medline:
4
1
2023
entrez:
21
11
2022
Statut:
ppublish
Résumé
The Greater Toronto Area (GTA) is home to 39% of Canada's population living with HIV. To identify gaps in access and engagement in care and treatment, we assessed the care cascade of women living with HIV (WLWH) in the GTA versus the rest of Ontario and Canada (in this case: Quebec and British Columbia). We analyzed 2013-2015 self-reported baseline data from the Canadian HIV Women's Sexual and Reproductive Health Cohort Study for six care cascade stages: linked to care, retained in care, initiated antiretroviral therapy (ART), currently on ART, ART adherence (≥90%), and undetectable (<50 copies/mL). Multivariable logistic regression was used to reveal associations with being undetectable. Comparing the GTA to the rest of Ontario and Canada, respectively: 96%, 98%, 100% were linked to care; 92%, 94%, 98% retained in care; 72%, 89%, 96% initiated ART; 67%, 81%, 90% were currently using ART; 53%, 66%, 77% were adherent; 59%, 69%, 81% were undetectable. Factors associated with viral suppression in the multivariable model included: living outside of the GTA (Ontario: aOR = 1.72, 95% CI: 1.09-2.72; Canada: aOR = 2.42, 95% CI: 1.62-3.62), non-Canadian citizenship (landed immigrant/permanent resident: aOR = 3.23, 95% CI: 1.66-6.26; refugee/protected person/other status: aOR = 4.77, 95% CI: 1.96-11.64), completed high school (aOR = 1.77, 95% CI: 1.15-2.73), stable housing (aOR = 2.13, 95% CI: 1.33-3.39), income of ≥$20,000 (aOR = 1.52, 95% CI: 1.00-2.31), HIV diagnosis <6 years (6-14 years: aOR = 1.75, 95% CI: 1.16-2.63; >14 years: aOR = 1.87, 95% CI: 1.19-2.96), and higher resilience (aOR = 1.02, 95% CI: 1.00-1.04). WLWH living in the GTA had lower rates of viral suppression compared to the rest of Ontario and Canada even after adjustment of age, ethnicity, and HIV diagnosis duration. High-impact programming for WLWH in the GTA to improve HIV outcomes are greatly needed.
Sections du résumé
BACKGROUND
The Greater Toronto Area (GTA) is home to 39% of Canada's population living with HIV. To identify gaps in access and engagement in care and treatment, we assessed the care cascade of women living with HIV (WLWH) in the GTA versus the rest of Ontario and Canada (in this case: Quebec and British Columbia).
METHODS
We analyzed 2013-2015 self-reported baseline data from the Canadian HIV Women's Sexual and Reproductive Health Cohort Study for six care cascade stages: linked to care, retained in care, initiated antiretroviral therapy (ART), currently on ART, ART adherence (≥90%), and undetectable (<50 copies/mL). Multivariable logistic regression was used to reveal associations with being undetectable.
RESULTS
Comparing the GTA to the rest of Ontario and Canada, respectively: 96%, 98%, 100% were linked to care; 92%, 94%, 98% retained in care; 72%, 89%, 96% initiated ART; 67%, 81%, 90% were currently using ART; 53%, 66%, 77% were adherent; 59%, 69%, 81% were undetectable. Factors associated with viral suppression in the multivariable model included: living outside of the GTA (Ontario: aOR = 1.72, 95% CI: 1.09-2.72; Canada: aOR = 2.42, 95% CI: 1.62-3.62), non-Canadian citizenship (landed immigrant/permanent resident: aOR = 3.23, 95% CI: 1.66-6.26; refugee/protected person/other status: aOR = 4.77, 95% CI: 1.96-11.64), completed high school (aOR = 1.77, 95% CI: 1.15-2.73), stable housing (aOR = 2.13, 95% CI: 1.33-3.39), income of ≥$20,000 (aOR = 1.52, 95% CI: 1.00-2.31), HIV diagnosis <6 years (6-14 years: aOR = 1.75, 95% CI: 1.16-2.63; >14 years: aOR = 1.87, 95% CI: 1.19-2.96), and higher resilience (aOR = 1.02, 95% CI: 1.00-1.04).
CONCLUSION
WLWH living in the GTA had lower rates of viral suppression compared to the rest of Ontario and Canada even after adjustment of age, ethnicity, and HIV diagnosis duration. High-impact programming for WLWH in the GTA to improve HIV outcomes are greatly needed.
Identifiants
pubmed: 36411243
doi: 10.1177/09564624221108034
pmc: PMC9806481
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4-17Subventions
Organisme : CIHR
Pays : Canada
Références
J Adolesc Health. 2007 Jan;40(1):96-8
pubmed: 17185215
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):44-51
pubmed: 27434707
Can J Public Health. 2018 Dec;109(5-6):800-809
pubmed: 30140981
PLoS Med. 2011 Nov;8(11):e1001124
pubmed: 22131907
Antivir Ther. 2017;22(4):325-335
pubmed: 27925609
Health Care Women Int. 2015;36(8):936-64
pubmed: 25256222
AIDS Patient Care STDS. 2012 Feb;26(2):108-15
pubmed: 22149767
AIDS Behav. 2019 Aug;23(8):2025-2036
pubmed: 30343422
Can J Infect Dis Med Microbiol. 2012 Spring;23(1):9-14
pubmed: 23449134
AIDS Patient Care STDS. 2015 Nov;29(11):582-90
pubmed: 26505968
Medicine (Baltimore). 2018 Jun;97(22):e10562
pubmed: 29851775
Prog Community Health Partnersh. 2018;12(1):21-34
pubmed: 29606690
PLoS One. 2014 Dec 26;9(12):e115277
pubmed: 25541682
Am J Prev Med. 1994 Mar-Apr;10(2):77-84
pubmed: 8037935
J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):226-236
pubmed: 29916960
J Health Psychol. 1997 Jul;2(3):335-51
pubmed: 22013026
J Nurs Meas. 1993 Winter;1(2):165-78
pubmed: 7850498
BMC Infect Dis. 2016 Oct 21;16(1):590
pubmed: 27769246
AIDS. 2018 Jan 2;32(1):17-23
pubmed: 29112073
PLoS One. 2019 Jan 4;14(1):e0210096
pubmed: 30608962
AIDS Behav. 2019 Sep;23(9):2326-2336
pubmed: 31324996
BMC Res Notes. 2017 Mar 24;10(1):138
pubmed: 28340606
Int J Environ Res Public Health. 2020 Nov 11;17(22):
pubmed: 33187304
BMC Public Health. 2019 Dec 16;19(1):1683
pubmed: 31842822
PLoS One. 2012;7(7):e40793
pubmed: 22829885
Harm Reduct J. 2019 Jul 18;16(1):47
pubmed: 31319894
PLoS One. 2017 Sep 28;12(9):e0184708
pubmed: 28957412
PLoS One. 2020 Oct 1;15(10):e0239190
pubmed: 33001986
Curr Opin HIV AIDS. 2015 Nov;10(6):420-9
pubmed: 26352393